HOME   |    PDF   |   


Management of polycystic ovary syndrome among Indian women using myo‐inositol and D-chiro-inositol



Lila Vyas1, Anagha Pai Raiturker2, Shilpi Sud3, Poonam Goyyal4, Mahesh Abhyankar5,*, Santosh Revankar5 & Silki Walia5



1Vyas clinic, Jaipur, India; 2Pairaiturkar clinic, Pune, India; 3Safal Hospital, Nagpur, India; 4Panchsheel Hospital, New Delhi, India; 5USV Private Limited, Mumbai, India; *Corresponding author



Lila Vyas E-mail: lilavyas_149@yahoo.com Anagha Pai Raiturker E-mail: dranaghapai@gmail.com Shilpi Sud E-mail: sun_shilpi@yahoo.com Poonam Goyyal E-mail: goyalpoonam29@gmail.com Mahesh Abhyankar E-mail: drmahesh.abhyankar@usv.in Santosh Revankar E-mail: santosh.revankar@usv.in Silki Walia E-mail: silki.walia@usv.in


Article Type

Research Article



Received October 21, 2021; Revised January 3, 2022; Accepted January 3, 2022, Published February 28, 2022



Myo-Inositol and D-chiro-inositol (MI-DCI) are used in the treatment of polycystic ovary syndrome (PCOS) due to their insulin-sensitizing actions. Therefore, it is of interest to evaluate the treatment patterns, clinical effectiveness and safety of MI-DCI combination in management of PCOS in Indian women .Data from 50 healthcare centers across India between September 2019 and February 2020 were used in the study. Women aged 12-45 years diagnosed with PCOS, who had received MI-DCI (550-150 mg) were included. The outcome parameters were change in weight, luteinizing hormone (LH)/follicle stimulating hormone (FSH) ratio, hirsutism, blood glucose and insulin levels, HOMA-IR, and lipid profile. 283 women (mean age: 27.74 years; body mass index: 26.89 kg/m2); of which 197 (69.61%) reported reduction in weight after treatment with MI-DCI. The proportion of hirsutism score reduced after treatment, no hirsutism increased from 31.07% to 50.51% and the severe reduced from 4.85% to zero and moderate from 32.52% to 6.12%. There was a significant reduction in LH:FSH ratio (mean difference: 0.25 mg/dL; p=0.021), free testosterone (mean difference: 1.49; p<0.001) and dehydroepiandrosterone (mean difference: 21.49; P<0.001) levels after regular use of MI-DCI tablets.Treatment with MI-DCI resulted in significant improvement in insulin, HOMA score, FPG, PPG and lipid profile. The therapy restored menstruation and spontaneous ovulation and significantly attenuated the LH/FSH ratio. Thus, MI-DCI (550-150 mg) has shown multidimensional benefits in improving the hormonal, glycemic, and lipid profile of women with PCOS with considerable efficacy and tolerability.



Women health, reproductive health, insulin sensitization, ovulation



Vyas et al. Bioinformation 18(2): 103-110 (2022)


Edited by

P Kangueane






Biomedical Informatics



This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.